Study of MEN1703 for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called MEN1703, alone or with another drug (glofitamab), for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of aggressive B-cell lymphoma (like DLBCL) that has come back or not responded to at least two prior treatments.
- You have at least one tumor that can be measured on a CT or PET scan.
- You have not had a specific type of immunotherapy called an anti-CD3xCD20 bispecific antibody (unless you are in a specific group that allows it).
- You are generally healthy enough for daily activities (ECOG score 0, 1, or 2).
- Your kidney, liver, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called glofitamab, which helps your immune system attack lymphoma cells. It is for people with aggressive B-cell lymphoma that has grown after standard treatments. The study uses a biopsy to tailor the treatment during therapy.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This phase 1 trial tests an investigational treatment called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to previous therapies. The goal is to see if the drug is safe and effective.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This trial tests a combination of four drugs (G-Pola-GemOx) for people with aggressive B-cell lymphoma who have not had chemotherapy before. The goal is to see if this new treatment can help control the cancer.
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Hear when a new Non-Hodgkin Lymphoma, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.